New drug combo may shield liver during cancer surgery
NCT ID NCT07150624
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called polyene phosphatidylcholine, given before and after surgery, can protect the liver in people with liver cancer. About 96 participants will receive either the drug combo or standard care. The goal is to see if it reduces liver injury after laparoscopic liver removal.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app tame Alcohol-Related liver disease?
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can a smarter scan make liver testing more reliable?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- A new Anti-Rejection strategy may spare kidney function after liver transplant
- AI-Powered surveillance may outsmart liver cancer recurrence